Trial Profile
A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs UV 1 (Primary) ; Sargramostim
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms UV1hTERT2012P
- Sponsors Ultimovacs AS
- 04 Apr 2024 According to an Ultimovacs ASA media release, data from the study will be presented in a poster at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.
- 25 May 2022 According to an Ultimovacs AS media release, data from this study presented at the Journal for ImmunoTherapy of Cancer and was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting.
- 10 May 2022 According to an Ultimovacs AS media release, data from this trial will be presented as a poster at the upcoming Cancer Immunotherapy (CIMT) annual meeting 2022.